The combination of toll-like receptor 4 and 7 agonists suppresses colon carcinoma via tumor microenvironment modulation and potential granzyme-mediated cytotoxicity

Background Overcoming the immunosuppressive tumor microenvironment (TME) is a major challenge in cancer immunotherapy. Building on combined TLR agonist studies, we introduce compound 2 as a novel TLR7 agonist and test it alone and with a TLR4 agonist for TME reprogramming and antitumor immunity in colon carcinoma. Methods The activity of compound 2 and its combined effects with TLR4 agonist were first evaluated in vitro by assessing NF-κB signaling activation, dendritic cell maturation and proinflammatory cytokine production. In vivo , compound 2 and a TLR4 agonist were intratumorally co-delivered to CT26 tumor-bearing mice. Tumor growth and survival were monitored. The intratumoral immune landscape was profiled via flow cytometry, and transcriptomic analysis was performed to elucidate underlying mechanisms. Systemic toxicity was assessed by hematological and organ toxicity tests. Results Compound 2 exhibited TLR7 agonist activity, and its combination with a TLR4 agonist markedly enhanced NF-κB signaling and, in vitro , induced maturation of bone-marrow-derived dendritic cells, leading to elevated proinflammatory cytokines. In mouse models, this combination significantly suppressed tumor growth and prolonged survival. Immune profiling revealed treatment-associated shifts in the relative frequencies of intratumoral immune populations, including higher frequencies of cytotoxic T cells, natural killer cells, and M1 macrophages, and lower frequencies of monocytic cells, M2 macrophages, CD11b + Siglec-H + cells and CD11b + CD11c + MHC-II + cells, and CD8 + PD-1 + T cells. Because these values are relative frequencies of live cells, they do not establish changes in absolute abundance. Transcriptomic analysis revealed enrichment of granzyme-mediated apoptotic pathways, consistent with known cytotoxic lymphocyte effector mechanisms, and gene signatures associated with reduced tumor burden. Conclusion Co-activation of TLR7 by compound 2 and TLR4 represents a promising strategy to shift the intratumoral immune balance toward cytotoxic effector frequencies, and extends earlier combined TLR agonist approaches. This approach is associated with shifts in the tumor microenvironment and with enhanced cytotoxic immunity, suppresses tumor growth, and was well tolerated at the doses tested, highlighting its potential for enhancing immunotherapy in accessible tumors such as colon carcinoma.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-19
DOI
https://doi.org/10.3389/fimmu.2026.1911644
Primary Topic
Immunotherapy and Immune Responses
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The combination of toll-like receptor 4 and 7 agonists suppresses colon carcinoma via tumor microenvironment modulation and potential granzyme-mediated cytotoxicity

Xiongyan Meng, Chengli Zong, Yong Rao, Juan Hou et al.
Frontiers in Immunology
Immunotherapy and Immune Responses
article

The combination of toll-like receptor 4 and 7 agonists suppresses colon carcinoma via tumor microenvironment modulation and potential granzyme-mediated cytotoxicity

Xiongyan Meng, Chengli Zong, Yong Rao, Juan Hou, Xin Wang, Changcai Teng, Qi Gao
article en

Abstract

Background Overcoming the immunosuppressive tumor microenvironment (TME) is a major challenge in cancer immunotherapy. Building on combined TLR agonist studies, we introduce compound 2 as a novel TLR7 agonist and test it alone and with a TLR4 agonist for TME reprogramming and antitumor immunity in colon carcinoma. Methods The activity of compound 2 and its combined effects with TLR4 agonist were first evaluated in vitro by assessing NF-κB signaling activation, dendritic cell maturation and proinflammatory cytokine production. In vivo , compound 2 and a TLR4 agonist were intratumorally co-delivered to CT26 tumor-bearing mice. Tumor growth and survival were monitored. The intratumoral immune landscape was profiled via flow cytometry, and transcriptomic analysis was performed to elucidate underlying mechanisms. Systemic toxicity was assessed by hematological and organ toxicity tests. Results Compound 2 exhibited TLR7 agonist activity, and its combination with a TLR4 agonist markedly enhanced NF-κB signaling and, in vitro , induced maturation of bone-marrow-derived dendritic cells, leading to elevated proinflammatory cytokines. In mouse models, this combination significantly suppressed tumor growth and prolonged survival. Immune profiling revealed treatment-associated shifts in the relative frequencies of intratumoral immune populations, including higher frequencies of cytotoxic T cells, natural killer cells, and M1 macrophages, and lower frequencies of monocytic cells, M2 macrophages, CD11b + Siglec-H + cells and CD11b + CD11c + MHC-II + cells, and CD8 + PD-1 + T cells. Because these values are relative frequencies of live cells, they do not establish changes in absolute abundance. Transcriptomic analysis revealed enrichment of granzyme-mediated apoptotic pathways, consistent with known cytotoxic lymphocyte effector mechanisms, and gene signatures associated with reduced tumor burden. Conclusion Co-activation of TLR7 by compound 2 and TLR4 represents a promising strategy to shift the intratumoral immune balance toward cytotoxic effector frequencies, and extends earlier combined TLR agonist approaches. This approach is associated with shifts in the tumor microenvironment and with enhanced cytotoxic immunity, suppresses tumor growth, and was well tolerated at the doses tested, highlighting its potential for enhancing immunotherapy in accessible tumors such as colon carcinoma.

Frontiers in ImmunologyVol. 17
Binzhou Medical University (CN), Hainan University (CN)
Immunotherapy and Immune Responses
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon